JP2012509344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509344A5 JP2012509344A5 JP2011537608A JP2011537608A JP2012509344A5 JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5 JP 2011537608 A JP2011537608 A JP 2011537608A JP 2011537608 A JP2011537608 A JP 2011537608A JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- amino acid
- acid sequence
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11654108P | 2008-11-20 | 2008-11-20 | |
| US61/116,541 | 2008-11-20 | ||
| PCT/US2009/065084 WO2010059787A1 (en) | 2008-11-20 | 2009-11-19 | Therapeutic protein formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509344A JP2012509344A (ja) | 2012-04-19 |
| JP2012509344A5 true JP2012509344A5 (enExample) | 2015-04-02 |
| JP5726085B2 JP5726085B2 (ja) | 2015-05-27 |
Family
ID=41683048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537608A Active JP5726085B2 (ja) | 2008-11-20 | 2009-11-19 | 治療用タンパク質製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120027772A1 (enExample) |
| EP (1) | EP2358393A1 (enExample) |
| JP (1) | JP5726085B2 (enExample) |
| KR (1) | KR101676887B1 (enExample) |
| CN (2) | CN107184976A (enExample) |
| AU (1) | AU2009316592B2 (enExample) |
| BR (1) | BRPI0921947A2 (enExample) |
| CA (1) | CA2737045C (enExample) |
| HK (1) | HK1244426A1 (enExample) |
| IL (1) | IL211670A (enExample) |
| MX (1) | MX2011004748A (enExample) |
| WO (1) | WO2010059787A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007308792B2 (en) | 2006-10-27 | 2013-01-24 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| SMT201700547T1 (it) * | 2010-06-15 | 2018-01-11 | Genmab As | Coniugati di farmaco anticorpo umano contro il fattore tissutale |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| CA2853112C (en) * | 2011-10-25 | 2018-08-21 | Onclave Therapeutics Limited | Antibody formulations and methods |
| EP3148986A4 (en) * | 2014-05-27 | 2018-01-10 | Navigen, Inc. | Arf6 inhibitors and methods of synthesis and use thereof |
| JP2018533930A (ja) * | 2015-10-02 | 2018-11-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
| US20200289621A1 (en) * | 2017-09-22 | 2020-09-17 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| EP3774881A1 (en) * | 2018-04-02 | 2021-02-17 | Amgen Inc. | Erenumab compositions and uses thereof |
| CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| AU2022262421A1 (en) * | 2021-04-23 | 2023-10-19 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| CN118812648A (zh) * | 2024-07-28 | 2024-10-22 | 青岛大学附属医院 | 一种基于steap-1的t细胞抗原表位肽及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1261376A1 (en) * | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| EP1391209A4 (en) * | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
| AU2002324556A1 (en) * | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP2003128575A (ja) * | 2001-10-25 | 2003-05-08 | Mochida Pharmaceut Co Ltd | 脳腫瘍治療剤 |
| EP3192528A1 (en) * | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| EP1558647B1 (en) * | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| NZ550816A (en) * | 2004-04-22 | 2009-12-24 | Agensys Inc | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2007308792B2 (en) * | 2006-10-27 | 2013-01-24 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
-
2009
- 2009-11-19 US US13/130,277 patent/US20120027772A1/en not_active Abandoned
- 2009-11-19 MX MX2011004748A patent/MX2011004748A/es active IP Right Grant
- 2009-11-19 BR BRPI0921947-1A patent/BRPI0921947A2/pt not_active IP Right Cessation
- 2009-11-19 EP EP09760400A patent/EP2358393A1/en not_active Withdrawn
- 2009-11-19 AU AU2009316592A patent/AU2009316592B2/en not_active Ceased
- 2009-11-19 CN CN201710300195.5A patent/CN107184976A/zh active Pending
- 2009-11-19 JP JP2011537608A patent/JP5726085B2/ja active Active
- 2009-11-19 WO PCT/US2009/065084 patent/WO2010059787A1/en not_active Ceased
- 2009-11-19 KR KR1020117011516A patent/KR101676887B1/ko not_active Expired - Fee Related
- 2009-11-19 CA CA2737045A patent/CA2737045C/en not_active Expired - Fee Related
- 2009-11-19 CN CN2009801548665A patent/CN102281901A/zh active Pending
-
2011
- 2011-03-10 IL IL211670A patent/IL211670A/en not_active IP Right Cessation
-
2015
- 2015-11-20 US US14/948,073 patent/US20160068607A1/en not_active Abandoned
-
2018
- 2018-03-05 HK HK18103142.1A patent/HK1244426A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7472210B2 (ja) | 有効性の改善および毒性の減少のための、抗体およびｓｎ－３８からなるイムノコンジュゲートの投薬 | |
| JP7245239B2 (ja) | Ｒｏｒ１抗体免疫複合体 | |
| JP2015528818A5 (enExample) | ||
| ES2819573T3 (es) | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A | |
| JP2015527318A5 (enExample) | ||
| JP2015531750A5 (enExample) | ||
| ES2738700T3 (es) | Inmunoconjugados con un enlace escindible intracelularmente | |
| ES2988698T3 (es) | Conjugados de fracciones de unión a la camptotecina | |
| ES2892525T3 (es) | Uso neoadyuvante de conjugados anticuerpo-fármaco | |
| AU2014293670B2 (en) | Antibody-SN-38 immunoconjugates with a CL2A linker | |
| JP2019146572A5 (enExample) | ||
| JP2017503011A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| US20150018516A1 (en) | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer | |
| JP2015523380A5 (enExample) | ||
| JP2015527319A5 (enExample) | ||
| JP2011500725A5 (enExample) | ||
| JP2021521143A5 (enExample) | ||
| WO2017004144A1 (en) | Antibody-sn-38 immunoconjugates with a cl2a linker | |
| JP2022513684A5 (enExample) | ||
| JP2024530368A5 (enExample) | ||
| JP2011505371A5 (enExample) | ||
| WO2024145398A1 (en) | Antibody drug conjugates | |
| JP2015529656A5 (enExample) |